Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, October 14, 2026

Back to today

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.

SOLS $9.7B
Yet Another Value Podcast 84 clicks

From X

@StableBread

Fajasy on X

Elmet $ELMT won a ~$36M U.S. defense stockpile contract for metal its plants already make, while deliveries under its $2B stockpile contract wait on new supply. On September 30, Elmet announced the award from the Defense Logistics Agency (DLA), which manages the U.S. National Defense Stockpile. It covers TZM (titanium-zirconium-molybdenum alloy) billets, bar stock, and ingots, plus molybdenum and tungsten wire, materials used to make jet engine components. Elmet's $2B stockpile contract, announced September 14, is separate and covers tungsten concentrate, the upgraded ore a mine ships. The $36M is 27.4% of Elmet's $131.5M total backlog at July 3 ($36M / $131.5M), and the release doesn't say when deliveries start or how long the contract runs. On the slide for the $2B contract, Elmet's October 1 deck says Elmet "does not intend to begin delivering material into the National Defense Stockpile until sufficient incremental new supply is available." Elmet's supply agreement with Tungsten West (AIM: TUN) puts concentrate from Hemerdon, its tungsten mine in Devon, England, first in line for Elmet's DLA deliveries until Elmet's Nevada refinery is commissioned (targeted for 1H 2029). Elmet expects >1,000 tonnes a year of Hemerdon concentrate, and the mine targets full production by the end of Q1 2027. In September I treated $1.85B of the $2B ceiling as an upper bound, not orders Elmet has in hand, and the $36M sits outside the $2B entirely. So the stockpile's newest award goes to metal from Elmet's existing U.S. plants, while the $2B contract still waits on a mine in England that isn't at full production yet.
@MaiusPartners 1 click

Maius on X

Some $PSIX thoughts off the recent 8-K: The banking syndicate lifted committed capacity from $135m to $220m (+$85m), cut the SOFR margin from +2.60% to +1.80%, and pushed maturity from July 2027 to September 2029 (~26 months). Credit committees are structurally risk-averse. More exposure, less spread, and longer tenor only clears if they like the repayment case. So what are they underwriting that most equity investors still won’t touch? Two things the disclosures imply: 1) Weichai’s North American strategy is locked in. Change-of-control remains tied to Weichai keeping board control and ≥40% ownership (same economic threshold as before). The extension removes left-tail risk that Weichai pursues a different go-to-market path. 2) The extra capacity isn’t for today’s balance sheet. Net debt was essentially zero at Q2’26 (cash ~$70m, debt ~$73m). The new investor materials flag Prime Power as a deliverable for the first time—ranges that overlap $INIO’s data-center gas engines, a segment where $INIO recently highlighted as an area "Chinese players have historically struggled to break in" and hence command "100% market share in several datacenter power ranges". As Bezos put it: your margin is my opportunity. Have a great weekend, everybody!
@StableBread

Fajasy on X

If ur reading a write-up and they don't include a valuation range, more often than not: 1) They're lying to themselves. E.g. only pitching bull case. "The next 10x." $GRAB a couple years ago. 2) They're lying to you, the reader. E.g. not focusing on bear case enough. "It's asymmetric"... but actual downside if couple thing flops is 60%+. $FLNC just 2-3 months ago. 3) They have no clue and prob conclude by saying "position as small speculative bet" to be in a win-win scenario to gain subs. $CCXI today... Multiple based valuation is the simple/lazy route and easier to defend, yet less practical. Absolute valuations like DCF or Penman REV forces you to think more through scenarios and the business itself, which is what's actually useful because it's more subjective.

Investor Letters

All letters

LQDA: finer powder, higher doses

Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…

LQDA $2.4B
Trade Ideas Flow 4 clicks
SRTA · long

Strata Critical Medical INC

Strata Critical Medical, SRTA, supplies organ-transport products tied to U.S. transplant growth.

SRTA $382M
Value Investors Club 3 clicks

Deep Dive: Inter & Co

Inter & Co, Brazil’s second-largest neobank, grew over 20% with controlled delinquencies and 15% book-value compounding while trading at…

INTR $3B
Capitalist Letters 7 clicks

You Understand Now, Why You Came This Way

Brazil’s October 25 runoff puts Bolsonaro’s likely victory at the center of a bullish regional-stock case; Golar LNG (GLNG) also reports…

GLNG $4.7B
WHAT ARE WE DOING? “Contrarians At The Gate” 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 231

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.